Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Refractory Differentiated Thyroid Gland Carcinoma: full-pipeline trial registry
1 of 2 indexed Refractory Differentiated Thyroid Gland Carcinoma trials are currently recruiting.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Refractory Differentiated Thyroid Gland Carcinoma: 2 US clinical trials tracked, 1 recruiting.
Refractory Differentiated Thyroid Gland Carcinoma is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is ECOG-ACRIN Cancer Research Group, running 1 of these trials.
Enrollment posture brief
Registry condition refractory-differentiated-thyroid-gland-carcinoma
OPEN 1 | RECR 50% | LATE 1 | EARLY 1 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Refractory Differentiated Thyroid Gland Carcinoma lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Refractory Differentiated Thyroid Gland Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Refractory Differentiated Thyroid Gland Carcinoma is recruiting above its size-band peers.
1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
ECOG-ACRIN Cancer Research Group
NCT06475989
Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer
National Cancer Institute (NCI)
NCT03914300
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Refractory Differentiated Thyroid Gland Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Refractory Differentiated Thyroid Gland Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Refractory Differentiated Thyroid Gland Carcinoma page
2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Refractory Differentiated Thyroid Gland Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- ECOG-ACRIN Cancer Research Group sponsors the most Refractory Differentiated Thyroid Gland Carcinoma trials on record, review their full trial history before evaluating a specific study. See ECOG-ACRIN Cancer Research Group's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Refractory Differentiated Thyroid Gland Carcinoma condition card totals 2 registered trials; most-linked intervention Magnetic Resonance Imaging; top US site state Missouri. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.